TSC2

Across TCGA pan-cancer cohorts, TSC2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TSC2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TSC2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TSC2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where TSC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TSC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	−0.172	<.001	11	view →
COAD	All	All	−0.343	<.001	8	view →
LSCC	All	III,IV	−0.255	<.001	8	view →
OV	All	All	−0.255	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TSC2–CCRCC

Open the CCRCC breakdown →